Incomplete testosterone suppression in prostate cancer

New England Journal of Medicine

Volumn 363, Issue 20, 2010, Pages 1976-

  Crawford, E David ^a   Rove, Kyle O ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; GONADORELIN ANTAGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADVERSE OUTCOME; ANDROGEN DEPRIVATION THERAPY; CANCER SURVIVAL; CASTRATION; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; INCOMPLETE TESTOSTERONE SUPPRESSION; LETTER; MALE; ORCHIECTOMY; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE;

EID: 78149486596     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1010187     Document Type: Letter

References (4)

1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
2. Faris JE, Smith MR. Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes 2010;17:240-6.
3. Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007;178:1290-5. (Pubitemid 47368393)
4. Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2010;105:648-51.